Browsing Cardiología by Subject "Benzhydryl Compounds"

Now showing items 1-3 of 3

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Packer, Milton; Anker, Stefan D.; Butler, Javed; Filippatos, Gerasimos; Pocock, Stuart J.; Carson, Peter; Januzzi, James L.; Verma, Subodh; Tsutsui, Hiroyuki; Brueckmann, Martina; Jamal, Waheed; Kimura, Karen; Schnee, Janet; Zeller, Cordula; Cotton, Daniel; Bocchi, Edimar; Böhm, Michael; Choi, Dong-Ju; Perrone, Sergio Víctor; EMPEROR-Reduced Trial Investigators (Massachusetts Medical Society, 2020-10-08)

Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes. More evidence is needed regarding the effects ...
Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved

Anker, Stefan D.; Butler, Javed; Usman, Muhammad Shariq; Filippatos, Gerasimos; Ferreira, João Pedro; Bocchi, Edimar; Böhm, Michael; Brunner-La Rocca, Hans Pieter; Choi, Dong-Ju; Chopra, Vijay; Chuquiure, Eduardo; Giannetti, Nadia; Gomez-Mesa, Juan Esteban; Janssens, Stefan; Januzzi, James L.; González-Juanatey, José R.; Merkely, Bela; Nicholls, Stephen J.; Perrone, Sergio Víctor; Piña, Ileana L. (Nature Publishing Company, 2022-12)

The EMPEROR-Preserved trial showed that the sodium-glucose co-transporter 2 inhibitor empagliflozin significantly reduces the risk of cardiovascular death or hospitalization for heart failure (HHF) in heart failure patients ...
Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial

Anker, Stefan D.; Butler, Javed; Filippatos, Gerasimos; Waheed, Jamal; Salsali, Afshin; Schnee, Janet; Kimura, Karen; Zeller, Cordula; Jyothis, George; Brueckmann, Martina; Zannad, Faiez; Packer, Milton; EMPEROR-Preserved Trial Committees and Investigators (Wiley, 2019-09-16)

Background: The principal biological processes that characterize heart failure with a preserved ejection fraction (HFpEF) are systemic inflammation, epicardial adipose tissue accumulation, coronary microcirculatory ...

Browsing Cardiología by Subject "Benzhydryl Compounds"

Browsing Cardiología by Subject "Benzhydryl Compounds"

Search DSpace

Browse

All of DSpace

This Community

My Account